PMC:7212965 / 24749-25636 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T104","span":{"begin":52,"end":60},"obj":"Disease"}],"attributes":[{"id":"A104","pred":"mondo_id","subj":"T104","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Abdominal pain\nA total of 15 studies including 4031 COVID-19 patients (confirmed by laboratory RT-PCR testing) were included in the overall analysis for abdominal pain.21 , 23 , 27 , 37 , 50 , 54 , 55 , 59 , 63 , 69, 70, 71, 72, 73 , 76 The pooled prevalence of abdominal pain was 3.6% (95% CI, 3.0%–4.3%). A subgroup analysis of 1584 patients from the United States, Australia, South Korea, and The Netherlands, demonstrated a slightly higher pooled prevalence of 5.3% (95% CI, 4.2%–6.6)% compared with studies from China 2.7% (95% CI, 2.0%–3.4%), which included 10 studies of 2447 patients.37 , 59 , 63 , 69 , 70 The symptoms were variably described as stomachache, epigastric pain, and abdominal discomfort, without further details regarding the quality or nature of pain (Figure 3 and Supplementary Figure 8).\nFigure 3 Forest plot of the prevalence of abdominal pain in all patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T192","span":{"begin":15,"end":16},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T193","span":{"begin":102,"end":109},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T194","span":{"begin":178,"end":180},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T195","span":{"begin":221,"end":223},"obj":"http://purl.obolibrary.org/obo/CLO_0054055"},{"id":"T196","span":{"begin":307,"end":308},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T197","span":{"begin":426,"end":427},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Abdominal pain\nA total of 15 studies including 4031 COVID-19 patients (confirmed by laboratory RT-PCR testing) were included in the overall analysis for abdominal pain.21 , 23 , 27 , 37 , 50 , 54 , 55 , 59 , 63 , 69, 70, 71, 72, 73 , 76 The pooled prevalence of abdominal pain was 3.6% (95% CI, 3.0%–4.3%). A subgroup analysis of 1584 patients from the United States, Australia, South Korea, and The Netherlands, demonstrated a slightly higher pooled prevalence of 5.3% (95% CI, 4.2%–6.6)% compared with studies from China 2.7% (95% CI, 2.0%–3.4%), which included 10 studies of 2447 patients.37 , 59 , 63 , 69 , 70 The symptoms were variably described as stomachache, epigastric pain, and abdominal discomfort, without further details regarding the quality or nature of pain (Figure 3 and Supplementary Figure 8).\nFigure 3 Forest plot of the prevalence of abdominal pain in all patients."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T107","span":{"begin":0,"end":14},"obj":"Phenotype"},{"id":"T108","span":{"begin":153,"end":167},"obj":"Phenotype"},{"id":"T109","span":{"begin":262,"end":276},"obj":"Phenotype"},{"id":"T110","span":{"begin":668,"end":683},"obj":"Phenotype"},{"id":"T111","span":{"begin":689,"end":709},"obj":"Phenotype"},{"id":"T112","span":{"begin":770,"end":774},"obj":"Phenotype"},{"id":"T113","span":{"begin":856,"end":870},"obj":"Phenotype"}],"attributes":[{"id":"A107","pred":"hp_id","subj":"T107","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A108","pred":"hp_id","subj":"T108","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A109","pred":"hp_id","subj":"T109","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A110","pred":"hp_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/HP_0410019"},{"id":"A111","pred":"hp_id","subj":"T111","obj":"http://purl.obolibrary.org/obo/HP_0002027"},{"id":"A112","pred":"hp_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/HP_0012531"},{"id":"A113","pred":"hp_id","subj":"T113","obj":"http://purl.obolibrary.org/obo/HP_0002027"}],"text":"Abdominal pain\nA total of 15 studies including 4031 COVID-19 patients (confirmed by laboratory RT-PCR testing) were included in the overall analysis for abdominal pain.21 , 23 , 27 , 37 , 50 , 54 , 55 , 59 , 63 , 69, 70, 71, 72, 73 , 76 The pooled prevalence of abdominal pain was 3.6% (95% CI, 3.0%–4.3%). A subgroup analysis of 1584 patients from the United States, Australia, South Korea, and The Netherlands, demonstrated a slightly higher pooled prevalence of 5.3% (95% CI, 4.2%–6.6)% compared with studies from China 2.7% (95% CI, 2.0%–3.4%), which included 10 studies of 2447 patients.37 , 59 , 63 , 69 , 70 The symptoms were variably described as stomachache, epigastric pain, and abdominal discomfort, without further details regarding the quality or nature of pain (Figure 3 and Supplementary Figure 8).\nFigure 3 Forest plot of the prevalence of abdominal pain in all patients."}

{"project":"2_test","denotations":[{"id":"32407808-32241899-43469292","span":{"begin":198,"end":200},"obj":"32241899"},{"id":"32407808-32149037-43469293","span":{"begin":213,"end":215},"obj":"32149037"},{"id":"32407808-32217556-43469294","span":{"begin":225,"end":227},"obj":"32217556"},{"id":"32407808-32149037-43469295","span":{"begin":607,"end":609},"obj":"32149037"}],"text":"Abdominal pain\nA total of 15 studies including 4031 COVID-19 patients (confirmed by laboratory RT-PCR testing) were included in the overall analysis for abdominal pain.21 , 23 , 27 , 37 , 50 , 54 , 55 , 59 , 63 , 69, 70, 71, 72, 73 , 76 The pooled prevalence of abdominal pain was 3.6% (95% CI, 3.0%–4.3%). A subgroup analysis of 1584 patients from the United States, Australia, South Korea, and The Netherlands, demonstrated a slightly higher pooled prevalence of 5.3% (95% CI, 4.2%–6.6)% compared with studies from China 2.7% (95% CI, 2.0%–3.4%), which included 10 studies of 2447 patients.37 , 59 , 63 , 69 , 70 The symptoms were variably described as stomachache, epigastric pain, and abdominal discomfort, without further details regarding the quality or nature of pain (Figure 3 and Supplementary Figure 8).\nFigure 3 Forest plot of the prevalence of abdominal pain in all patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T167","span":{"begin":0,"end":14},"obj":"Sentence"},{"id":"T168","span":{"begin":15,"end":306},"obj":"Sentence"},{"id":"T169","span":{"begin":307,"end":813},"obj":"Sentence"},{"id":"T170","span":{"begin":814,"end":887},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Abdominal pain\nA total of 15 studies including 4031 COVID-19 patients (confirmed by laboratory RT-PCR testing) were included in the overall analysis for abdominal pain.21 , 23 , 27 , 37 , 50 , 54 , 55 , 59 , 63 , 69, 70, 71, 72, 73 , 76 The pooled prevalence of abdominal pain was 3.6% (95% CI, 3.0%–4.3%). A subgroup analysis of 1584 patients from the United States, Australia, South Korea, and The Netherlands, demonstrated a slightly higher pooled prevalence of 5.3% (95% CI, 4.2%–6.6)% compared with studies from China 2.7% (95% CI, 2.0%–3.4%), which included 10 studies of 2447 patients.37 , 59 , 63 , 69 , 70 The symptoms were variably described as stomachache, epigastric pain, and abdominal discomfort, without further details regarding the quality or nature of pain (Figure 3 and Supplementary Figure 8).\nFigure 3 Forest plot of the prevalence of abdominal pain in all patients."}

{"project":"LitCovid-PubTator","denotations":[{"id":"581","span":{"begin":0,"end":14},"obj":"Disease"},{"id":"584","span":{"begin":878,"end":886},"obj":"Species"},{"id":"585","span":{"begin":856,"end":870},"obj":"Disease"},{"id":"595","span":{"begin":61,"end":69},"obj":"Species"},{"id":"596","span":{"begin":335,"end":343},"obj":"Species"},{"id":"597","span":{"begin":583,"end":591},"obj":"Species"},{"id":"598","span":{"begin":52,"end":60},"obj":"Disease"},{"id":"599","span":{"begin":153,"end":167},"obj":"Disease"},{"id":"600","span":{"begin":262,"end":276},"obj":"Disease"},{"id":"601","span":{"begin":655,"end":666},"obj":"Disease"},{"id":"602","span":{"begin":668,"end":683},"obj":"Disease"},{"id":"603","span":{"begin":770,"end":774},"obj":"Disease"}],"attributes":[{"id":"A581","pred":"tao:has_database_id","subj":"581","obj":"MESH:D015746"},{"id":"A584","pred":"tao:has_database_id","subj":"584","obj":"Tax:9606"},{"id":"A585","pred":"tao:has_database_id","subj":"585","obj":"MESH:D015746"},{"id":"A595","pred":"tao:has_database_id","subj":"595","obj":"Tax:9606"},{"id":"A596","pred":"tao:has_database_id","subj":"596","obj":"Tax:9606"},{"id":"A597","pred":"tao:has_database_id","subj":"597","obj":"Tax:9606"},{"id":"A598","pred":"tao:has_database_id","subj":"598","obj":"MESH:C000657245"},{"id":"A599","pred":"tao:has_database_id","subj":"599","obj":"MESH:D015746"},{"id":"A600","pred":"tao:has_database_id","subj":"600","obj":"MESH:D015746"},{"id":"A602","pred":"tao:has_database_id","subj":"602","obj":"MESH:C537170"},{"id":"A603","pred":"tao:has_database_id","subj":"603","obj":"MESH:D010146"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Abdominal pain\nA total of 15 studies including 4031 COVID-19 patients (confirmed by laboratory RT-PCR testing) were included in the overall analysis for abdominal pain.21 , 23 , 27 , 37 , 50 , 54 , 55 , 59 , 63 , 69, 70, 71, 72, 73 , 76 The pooled prevalence of abdominal pain was 3.6% (95% CI, 3.0%–4.3%). A subgroup analysis of 1584 patients from the United States, Australia, South Korea, and The Netherlands, demonstrated a slightly higher pooled prevalence of 5.3% (95% CI, 4.2%–6.6)% compared with studies from China 2.7% (95% CI, 2.0%–3.4%), which included 10 studies of 2447 patients.37 , 59 , 63 , 69 , 70 The symptoms were variably described as stomachache, epigastric pain, and abdominal discomfort, without further details regarding the quality or nature of pain (Figure 3 and Supplementary Figure 8).\nFigure 3 Forest plot of the prevalence of abdominal pain in all patients."}